← All cohorts · SARS-CoV-2 cohorts
NIH RECOVER-Adult Cohort
source record (JSON) · schema v2.0.0 · CC BY 4.0
Design notes & limitations. The flagship US Long COVID study: the largest prospective, controlled Long COVID cohort globally. Enrols SARS-CoV-2 positive adults across the full spectrum (asymptomatic through severe acute COVID) plus SARS-CoV-2 negative controls from the same communities. Standardised protocol across >200 sites with harmonised data collection, imaging, and biospecimen banking. Acute-phase and convalescent specimens banked — this is the most important specimen-banking Long COVID cohort. Multiple substudies are publishing as the cohort matures; add publications and observations iteratively as substudies report. The design is prospective but non-inception (many participants enrolled post-acutely with retrospective infection date); this is recorded in the design field. The denominator is defined (all enrolled with confirmed SARS-CoV-2 status) but the source population denominator is the catchment areas of the 200+ sites, not a closed population.
Identity & trigger
- Cohort id
recover-adult-long-covid- Aliases
- RECOVER, RECOVER-Adult, Researching COVID to Enhance Recovery
- Outbreak / event
- COVID-19 pandemic (2020–)
- Pathogen
- SARS-CoV-2 (Virus)
- Exposure ascertainment
- pcr
Design
- Design
- Prospective (non-inception)
- Denominator defined
- Yes
- Denominator method
- Nationwide multi-site US cohort enrolling SARS-CoV-2 positive and negative adults from >200 sites. Enrolment began in 2021, enrolling both acute and post-acute participants with retrospective infection ascertainment and prospective follow-up.
- Recruitment
- Mixed
- Time zero
- Date of first positive SARS-CoV-2 PCR or antigen test (month)
- Control group
- Unexposed (unmatched)
Size & attrition
- Enrolled
- 15000
- Analysed / enrolled
- n/r
- Max follow-up (months)
- 48
Biospecimens
- Specimens
- Yes
- Types
- serum, plasma, pbmc, whole_blood, urine, saliva
- Acute-phase specimens
- Yes
- Biobank
- active
- External access
- open application
Harmonized estimate layer
Curation status: none · 0 estimate(s). Download core estimates
Observations (3)
Symptoms
n=15000 Count
- Measure
- Fatigue sym:fatigue
- As worded
- “Cohort N enrolled: ~15,000 adults (SARS-CoV-2 positive and negative)”
- Population
- whole cohort · denominator Assessed at timepoint · N=n=15000
- Timing
- 0 mo (Acute) · ref N/A
- Method
- Registry linkage
- Comparator
- no comparator
- Comparability signature
- b4eedcf8b8 — measure sym:fatigue · Registry linkage · ref N/A · denom Assessed at timepoint · Acute · Count
- Provenance
- Horwitz 2023, Abstract & Methods (~15,000 adults to be enrolled across >200 US sites) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-21
Serum, plasma, PBMC, whole blood, urine, and saliva collected at enrolment and at scheduled follow-up visits from all ~15,000 participants. Acute-phase specimens available for those enrolled during acute COVID. Specimens stored at centralised RECOVER biorepository across multiple academic medical centres. Available to external researchers via application to the RECOVER biospecimen access committee. Qualitative
- Measure
- Fatigue sym:fatigue
- As worded
- “Biospecimen banking: acute and convalescent serum, plasma, PBMC, whole blood, urine, saliva from all participants”
- Population
- whole cohort · denominator Assessed at timepoint · N=measured, not reported
- Timing
- 0 mo (Acute) · ref not reported
- Method
- Lab assay
- Comparator
- no comparator
- Comparability signature
- fb9eb96a4e — measure sym:fatigue · Lab assay · ref not reported · denom Assessed at timepoint · Acute · Qualitative
- Provenance
- Horwitz 2023, Methods (biospecimen collection protocol; specimens collected at enrolment and follow-up visits) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-21
Functional outcomes
RECOVER is the only Long COVID cohort with a national US sampling frame, SARS-CoV-2 negative controls drawn from the same communities, standardised multi-site protocol, acute-phase biospecimens, and 4-year planned follow-up. This makes it the Tier-1 reference cohort for Long COVID. Qualitative
- Measure
- Any persistent symptom func:any-persistent-symptom
- As worded
- “Controlled design: SARS-CoV-2 positive vs. negative participants from same communities”
- Population
- whole cohort · denominator Assessed at timepoint · N=n=15000
- Timing
- 0 mo (Acute) · ref N/A
- Method
- Registry linkage
- Comparator
- Unexposed (unmatched): measured, not reported
- Comparability signature
- 6e376a029c — measure func:any-persistent-symptom · Registry linkage · ref N/A · denom Assessed at timepoint · Acute · Qualitative
- Provenance
- Horwitz 2023, Methods (SARS-CoV-2 positive and negative participants enrolled from same catchment areas) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-21
Publications
- Horwitz LI, Thaweethai T, Brosnahan KB, et al. (2023). Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design. PLoS ONE. PMID 36075778 · DOI 10.1371/journal.pone.0274991 primary
Provenance & verification
- Registration
- NCT05172024
- Funders
- National Institutes of Health (NIH), USA
- Related cohorts
- none
- Symptom-inventory scope
- Comprehensive inventory
- Last verified
- 2026-07-21 — OSMF research-tracker (web-verified against source)